Preventing ischemic stroke: Choosing the best strategy

Rishi Gupta, MD
Department of Neurology, Section of Stroke and Neurological Critical Care, The Cleveland Clinic Foundation

Derk W. Krieger, MD, PhD
Department of Neurology, Section of Stroke and Neurological Critical Care, The Cleveland Clinic Foundation

Address: Derk W. Krieger, MD, PhD, Department of Neurology, Section of Stroke and Neurological Critical Care, S91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail krieged@ccf.org

Dr. Krieger has indicated that he is on the speakers’ bureau of BMS and is a consultant for Boehringer Ingleheim.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Rishi Gupta, MD
Department of Neurology, Section of Stroke and Neurological Critical Care, The Cleveland Clinic Foundation

Derk W. Krieger, MD, PhD
Department of Neurology, Section of Stroke and Neurological Critical Care, The Cleveland Clinic Foundation

Address: Derk W. Krieger, MD, PhD, Department of Neurology, Section of Stroke and Neurological Critical Care, S91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail krieged@ccf.org

Dr. Krieger has indicated that he is on the speakers’ bureau of BMS and is a consultant for Boehringer Ingleheim.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Rishi Gupta, MD
Department of Neurology, Section of Stroke and Neurological Critical Care, The Cleveland Clinic Foundation

Derk W. Krieger, MD, PhD
Department of Neurology, Section of Stroke and Neurological Critical Care, The Cleveland Clinic Foundation

Address: Derk W. Krieger, MD, PhD, Department of Neurology, Section of Stroke and Neurological Critical Care, S91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail krieged@ccf.org

Dr. Krieger has indicated that he is on the speakers’ bureau of BMS and is a consultant for Boehringer Ingleheim.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.